PHASE 1 STUDY RESULTS OF M7824 (MSB0011359C), A BIFUNCTIONAL FUSION PROTEIN TARGETING TGF- AND PD-L1, AMONG PATIENTS WITH RECURRENT GLIOBLASTOMA (rGBM)
Publication
, Conference
Khasraw, M; Weller, M; Estelles, DL; Kolibaba, K; Lee, C; Gedye, C; De La Fuente, M; Vicente, D; Reardon, D; Ojalvo, L; Helwig, C; Groves, M ...
Published in: NEURO-ONCOLOGY
November 1, 2018
Duke Scholars
Published In
NEURO-ONCOLOGY
EISSN
1523-5866
ISSN
1522-8517
Publication Date
November 1, 2018
Volume
20
Start / End Page
4 / 4
Location
New Orleans, LA
Publisher
OXFORD UNIV PRESS INC
Conference Name
23rd Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO) / 3rd CNS Anticancer Drug Discovery and Development Conference
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Khasraw, M., Weller, M., Estelles, D. L., Kolibaba, K., Lee, C., Gedye, C., … Groves, M. (2018). PHASE 1 STUDY RESULTS OF M7824 (MSB0011359C), A BIFUNCTIONAL FUSION PROTEIN TARGETING TGF- AND PD-L1, AMONG PATIENTS WITH RECURRENT GLIOBLASTOMA (rGBM). In NEURO-ONCOLOGY (Vol. 20, pp. 4–4). New Orleans, LA: OXFORD UNIV PRESS INC.
Khasraw, Mustafa, Michael Weller, David Lorente Estelles, Kathryn Kolibaba, Chee Lee, Craig Gedye, Macarena De La Fuente, et al. “PHASE 1 STUDY RESULTS OF M7824 (MSB0011359C), A BIFUNCTIONAL FUSION PROTEIN TARGETING TGF- AND PD-L1, AMONG PATIENTS WITH RECURRENT GLIOBLASTOMA (rGBM).” In NEURO-ONCOLOGY, 20:4–4. OXFORD UNIV PRESS INC, 2018.
Khasraw M, Weller M, Estelles DL, Kolibaba K, Lee C, Gedye C, et al. PHASE 1 STUDY RESULTS OF M7824 (MSB0011359C), A BIFUNCTIONAL FUSION PROTEIN TARGETING TGF- AND PD-L1, AMONG PATIENTS WITH RECURRENT GLIOBLASTOMA (rGBM). In: NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2018. p. 4–4.
Khasraw, Mustafa, et al. “PHASE 1 STUDY RESULTS OF M7824 (MSB0011359C), A BIFUNCTIONAL FUSION PROTEIN TARGETING TGF- AND PD-L1, AMONG PATIENTS WITH RECURRENT GLIOBLASTOMA (rGBM).” NEURO-ONCOLOGY, vol. 20, OXFORD UNIV PRESS INC, 2018, pp. 4–4.
Khasraw M, Weller M, Estelles DL, Kolibaba K, Lee C, Gedye C, De La Fuente M, Vicente D, Reardon D, Ojalvo L, Helwig C, Gourmelon C, Groves M. PHASE 1 STUDY RESULTS OF M7824 (MSB0011359C), A BIFUNCTIONAL FUSION PROTEIN TARGETING TGF- AND PD-L1, AMONG PATIENTS WITH RECURRENT GLIOBLASTOMA (rGBM). NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2018. p. 4–4.
Published In
NEURO-ONCOLOGY
EISSN
1523-5866
ISSN
1522-8517
Publication Date
November 1, 2018
Volume
20
Start / End Page
4 / 4
Location
New Orleans, LA
Publisher
OXFORD UNIV PRESS INC
Conference Name
23rd Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO) / 3rd CNS Anticancer Drug Discovery and Development Conference
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences